{
    "id": 447,
    "fullName": "ERBB2 wild-type",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "Wild-type ERBB2 (HER2) indicates that no mutation has been detected within the ERBB2 (HER2) gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 2064,
        "geneSymbol": "ERBB2",
        "terms": [
            "ERBB2",
            "CD340",
            "HER-2",
            "HER-2/neu",
            "HER2",
            "MLN 19",
            "NEU",
            "NGL",
            "TKR1"
        ]
    },
    "variant": "wild-type",
    "createDate": "05/02/2014",
    "updateDate": "08/27/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 3044,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tykerb (lapatinib) inhibited proliferation of transformed cell lines expressing wild-type ERBB2 (HER2) in culture (PMID: 22046346).",
            "molecularProfile": {
                "id": 530,
                "profileName": "ERBB2 wild-type"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 621,
                    "pubMedId": 22046346,
                    "title": "Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22046346"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3045,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AEE788 inhibited proliferation of transformed cell lines expressing wild-type ERBB2 (HER2) in culture (PMID: 22046346).",
            "molecularProfile": {
                "id": 530,
                "profileName": "ERBB2 wild-type"
            },
            "therapy": {
                "id": 622,
                "therapyName": "AEE788",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 621,
                    "pubMedId": 22046346,
                    "title": "Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22046346"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14172,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tagrisso (osimertinib) treatment resulted in antitumor efficacy in cells overexpressing wild-type ERBB2 (HER2), demonstrating inhibition of ERBB2 (HER2) phosphorylation and cell growth in culture and tumor regression in mouse models overexpressing wild-type ERBB2, with an 80% reduction in tumor volume (PMID: 29298799).",
            "molecularProfile": {
                "id": 530,
                "profileName": "ERBB2 wild-type"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11487,
                    "pubMedId": 29298799,
                    "title": "Targeting HER2 Aberrations in Non-Small Cell Lung Cancer with Osimertinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29298799"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12661,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gilotrif (afatinib) inhibited growth and NRG1-beta induced ERBB3 (HER3), ERBB2 (HER2), and AKT phosphorylation, and increased apoptosis of cells transfected with ERBB3 (HER3) V855A and wild-type ERBB2 (HER2) in culture (PMID: 26689995).",
            "molecularProfile": {
                "id": 28812,
                "profileName": "ERBB2 wild-type ERBB3 V855A"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9926,
                    "pubMedId": 26689995,
                    "title": "Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26689995"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12663,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tarceva (erlotinib) inhibited growth of cells transfected with ERBB3 (HER3) V855A and wild-type ERBB2 (HER2) in the presence of NRG1-beta in culture, however, was less effective than other ERBB (HER) inhibitors (PMID: 26689995).",
            "molecularProfile": {
                "id": 28812,
                "profileName": "ERBB2 wild-type ERBB3 V855A"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9926,
                    "pubMedId": 26689995,
                    "title": "Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26689995"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12662,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Perjeta (pertuzumab) inhibited growth and NRG1-beta induced ERBB3 (HER3) and ERBB2 (HER2) phosphorylation in cells transfected with ERBB3 (HER3) V855A and wild-type ERBB2 (HER2) in culture (PMID: 26689995).",
            "molecularProfile": {
                "id": 28812,
                "profileName": "ERBB2 wild-type ERBB3 V855A"
            },
            "therapy": {
                "id": 856,
                "therapyName": "Pertuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9926,
                    "pubMedId": 26689995,
                    "title": "Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26689995"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14195,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transgenic mouse models with ERBB2 (HER2)-wild-type cells expressing EGFR exon 19 deletion demonstrated tumor growth inhibition and an improved progression-free survival when treated with Tagrisso (osimertinib) compared to treatment with Tarceva (erlotinib) (PMID: 29298799).",
            "molecularProfile": {
                "id": 29952,
                "profileName": "EGFR exon 19 del ERBB2 wild-type"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11487,
                    "pubMedId": 29298799,
                    "title": "Targeting HER2 Aberrations in Non-Small Cell Lung Cancer with Osimertinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29298799"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 530,
            "profileName": "ERBB2 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 1573,
            "profileName": "EGFR over exp ERBB2 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28812,
            "profileName": "ERBB2 wild-type ERBB3 V855A",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29952,
            "profileName": "EGFR exon 19 del ERBB2 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}